StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Moderna (MRNA) Stock Down 11% on Likely Disappointing Flu Vaccine Data, Seen as 'Undifferentiated' by Morgan Stanley
December 10, 2021 9:51 AM
Morgan Stanley analyst Matthew Harrison briefly weighed in on the preliminary flu vaccine data released by Moderna (NASDAQ: MRNA) this ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Hot Comments
Next Articles
Moderna (MRNA) and Australia Collaborate to Bring mRNA Manufacturing to Australia
December 14, 2021 5:50 AM
Moderna's (MRNA) COVID-19 Vaccine Manufactured in Korea by Samsung Granted Marketing Authorization from Ministry of Food and Drug Safety of Korea
December 14, 2021 5:46 AM
Moderna (MRNA) Stock Gains While Street Analysts Discuss What Comes Next Following Early Flu Vaccine Data
December 13, 2021 7:50 AM
Moderna (MRNA) Continues to Grind off Lows, Remains Down 5.5%
December 10, 2021 12:14 PM
Moderna (MRNA) to Supply an 20M Doses of COVID-19 Vaccine to COVAX for 2021
December 10, 2021 9:02 AM
